Enhancing CNS mitophagy: drug development and disease-relevant models

Krishayant S. Dhar,Brendan Townsend,Andrew P. Montgomery,Jonathan J. Danon,Julia K. Pagan,Michael Kassiou
DOI: https://doi.org/10.1016/j.tips.2024.09.002
IF: 17.638
2024-11-08
Trends in Pharmacological Sciences
Abstract:Mitophagy, the selective degradation of mitochondria, is impaired in many neurodegenerative diseases (NDs), resulting in an accumulation of dysfunctional mitochondria and neuronal damage. Although enhancing mitophagy shows promise as a therapeutic strategy, the clinical significance of mitophagy activators remains uncertain due to limited understanding and poor representation of mitophagy in the central nervous system (CNS). This review explores recent insights into which mitophagy pathways to target and the extent of modulation necessary to be therapeutic towards NDs. We also highlight the complexities of mitophagy in the CNS, highlighting the need for disease-relevant models. Last, we outline crucial aspects of in vitro models to consider during drug discovery, aiming to bridge the gap between preclinical research and clinical applications in treating NDs through mitophagy modulation.
pharmacology & pharmacy
What problem does this paper attempt to address?